Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3 -ITD/ NPM1 wt Patients - a Study By the NOPHO-DB-SHIP Consortium
Kaspers, Gertjan J.L., Wijnen, Noa E., Koedijk, Joost B., Ishimaru, Sae, Benedictus, Renske, Van Opstal, Ellen C., Van Tinteren, Harm, Zwaan, C. Michel, Biserna, Noha, Downs, Pamela, Duong, Yvonne, Kamel, Yasser Mostafa, Abrahamsson, Jonas, Arad-Cohen, Nira, Bodmer, Nicole, Castillo, Luis, Cheuk, Daniel, Costa, Vitor, De Moerloose, Barbara, Fernandez Navarro, Jose Maria, Fogelstrand, Linda, Goemans, Bianca F., Hasle, Henrik, Jonsson, Olafur G., Kovalova, Zhanna, Munthe-Kaas, Monica C., Norén-Nyström, Ulrika, Palmu, Sauli, Pasauliene, Ramune, Saks, Kadri, Tierens, Anne Maria, Turkiewicz, Dominik, Pronk, Cornelis Jan
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article